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a b s t r a c t
A novel series of coumarin-4-carboxylate ligands (2a–2l), their Ag(I) complexes (3a–3l) together with a
number of their phenanthroline adducts (4d, 4f and 4g) have been synthesised and characterised. The
ligands were prepared by either acid or base hydrolysis of their corresponding esters or by demethylation
of a methylated acid derivative. The esters (1a–1i) were synthesised by an aromatic electrophilic substi-
tution reaction between the conjugate base of substituted phenols and a vinyltriphenylphosphonium salt.
The novel series of Ag(I) carboxylate complexes were prepared by reaction of silver nitrate with the cou-
marin ligands in aqueous/alcohol solution. The Ag(I) phenanthroline adducts were prepared by reaction
of the Ag(I) complex with 1,10-phenanthroline in aqueous/alcohol solution. A selection of complexes
were screened for their in vitro antibacterial activity against Pseudomonas aeruginosa grown planktonical-
ly or as a biofilm as well as a number of other clinically important strains, Escherichia coli, MRSA and
Staphylococcus aureus. The activity against the P. aeruginosa biofilm was found to be significantly greater
than against the planktonic bacteria.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
The Centres for Disease Control and Prevention in America have
estimated that 2 million patients suffer from hospital-acquired
infections (HAIs) every year and from that number there are
approximately 100,000 deaths [1]. Hospital acquired infections re-
sult in significant levels of illness, death and financial cost to global
healthcare systems. Many HAIs are a side effect of medical treat-
ments such as surgery and the use of implanted medical devices
including prosthetic implants and central venous and urinary cath-
eters [2]. For the most part of the last decade, Methicillin-resistant
Staphylococcus aureus (MRSA) was the leading cause of HAIs in Ire-
land [3]. However, another bacterium, Pseudomonas aeruginosa, is
of increasing concern worldwide with for example 200,000 HAIs
directly related to that organism annually in the USA alone [4].
Bacteria such P. aeruginosa, Staphylococci and Escherichia coli that
can exist in biofilms exhibit extreme resistance compared to plank-
tonic or free moving bacteria as they are protected from the host’s
immune cells and from the action of antimicrobial agents. It is re-
ported that to kill bacteria in a biofilm requires 1000 times the
antibiotic dose necessary to kill a planktonic population of cells
[1]. Up to 65–80% of human infections are caused by biofilms
and these are often the underlying reason why treatment with
antibiotics can fail [5]. The ever-increasing problem of microbial
resistance means that there is a need to develop effective strategies
to prevent and control HAIs. One such approach is to synthesise
new antimicrobial agents that effectively inhibit the growth of
microorganisms and which can be used as additives in efficient
surface technologies such as coatings and paints and in topical
healthcare products. The use of antimicrobial coatings in the clin-
ical environment can aid in reducing the risk of cross contamina-
tion and transmission of microbes and also help overcome anti-
microbial drug resistance.
There is a renewed interest in the use of silver metal and sil-
ver(I) salts and compounds as antimicrobial agents. The antimicro-
bial activity of silver has long been known but the introduction of
penicillin in the 1940s meant that antibiotics became the standard
treatment for infections and silver was no longer used. In the 1960s
silver nitrate was used to treat burn victims which led to the pro-
duction of silver sulfadiazine cream [6,7]. Silver in its ionic form,
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Ag(I), is active against a broad range of microbes even at low con-
centrations. Silver displays broad spectrum activity in which it at-
tacks multiple sites [8,9]. Studies have shown that the most
important mechanism of action of Ag(I) is based on its surface
binding and damage to the membrane function [10]. More recently
there are a number of products (topical creams, wound dressings,
sutures, catheters etc.) on the market that incorporate a form of sil-
ver to produce an antimicrobial effect. Topical treatments in the
form of hydrogels such as Silvasorb [11] and Silver Shield [12]
and wound dressings such as those from Acticoat™ [13], Aquacel
(acticoat) and Silvercel are alternatives to antibiotic treatment. A
number of silver antimicrobial additives manufactured for use in
many applications include AgIon from AgIon [14], and Biomaster
from Addmaster [15].
Whilst there are a number of biocidal silver products currently
available on the market, there is still a need to develop more effi-
cient cost effective silver-based products which offer long-term
antimicrobial activity. Using Ag(I) complexes which contain both
an organic (ligand) and inorganic (metal) component as the bio-
cidal additive represents a novel approach. The use of Ag(I) com-
plexes as biocidal additives in hygienic coatings has been
demonstrated by our previous work in which Ag(I) complexes of
coumarin-3-carboxylates were successfully incorporated into
sol–gel derived coatings. The thin-film coatings were found to be
effective against MRSA and Enterobacter cloacae WT6 strains at
low silver loadings (0.3% w/w) and were less toxic than coatings
containing silver nitrate and showed potential for use in the clini-
cal environment [16].
In this present work we have prepared a series of novel 4-cou-
marin carboxylate Ag(I) complexes. Coumarin and its derivatives
have shown a diverse array of biological activities including antimi-
crobial [17], chemotherapeutic [18,19], anticoagulant [20] and anti-
inflammatory [21]. A number of both naturally occurring and syn-
thetic coumarins including aminocoumarins [22,23], hydrox-
ycoumarins [24,25], pyranocoumarins [26], and furanocoumarins
[27] have been reported to have significant antimicrobial activity
against a wide range of microbes. Following on from our previous
work on a series of Ag(I) complexes of coumarin-3-carboxylates,
which have proven antimicrobial activity and potential as effective
biocides in hygienic coatings, a novel series of Ag(I) complexes of
coumarin-4-carboxylates has been synthesised and screened for
their antibacterial activity. In addition, three Ag(I) complexes con-
taining coumarin carboxylates and phenanthroline (phen) ligands
were also isolated and their antimicrobial activity investigated.
2. Experimental
2.1. Materials/general methods
All chemicals purchased from Sigma–Aldrich were reagent
grade and used without purification. Infrared spectra were re-
corded in the region of 4000–400 cm1, on a Nicolet Impact 410
Fourier-Transform Infrared spectrophotometer using Omnic soft-
ware. NMR spectra were obtained from both JOEL and Bruker spec-
trometers in d6-DMSO and were recorded in the region of 5 to
15 ppm from TMS for 1H NMR spectra and in the region of 33
to 233 ppm for 13C NMR spectra. NMR spectra run on a JOEL
JNM-LA300 (300 MHz 1H and 75 MHz 13C) spectrometer were re-
corded with a resolution of 0.0006 and 0.008 ppm for 1H NMR
and 13C NMR spectra respectively. NMR spectra run on a Bruker
Avance III spectrometer (300 MHz 1H and 75 MHz 13C) were re-
corded with a resolution of 0.000315 and 0.0037 ppm for 1H
NMR and 13C NMR respectively. NMR spectra run on a Bruker
Avance III 500 spectrometer (500 MHz 1H and 125 MHz 13C) were
recorded with a resolution of 0.00022 and 0.0036 ppm for 1H NMR
and 13C NMR respectively. UV–Visible (UV–Vis) spectra of the com-
pounds in DMSO were recorded on a Hitachi U-2001 Spectropho-
tometer. Atomic absorption spectroscopy (AAS) measurements
were taken on a Perkin–Elmer 460 AAS instrument (emission
wavelength 328.1 nm). Microanalytical data were provided by
the Microanalytical Laboratory, National University of Ireland Dub-
lin, Belfield, Dublin 4. Melting point values were recorded using a
Bibby SMP10 melting point apparatus and are uncorrected. Values
were taken up to 300 C. Molar conductivity was measured on a
Systronic conductivity bridge with a diptype cell, using
4  103 M solution of compounds in DMSO.
2.2. Syntheses of ligands
2.2.1. Synthesis of substituted esters 1a–1i
All of the esters 1a–1i (Fig. S1 in Supplementary data and Ta-
ble 1) were synthesised using the following general procedure.
The appropriate phenol (40 mmol) and triphenylphosphine (7.8 g,
30 mmol) were dissolved with stirring in dichloromethane
(80 ml). To this a solution of dimethyl acetylenedicarboxylate
(5 ml, 5.68 g, 40 mmol) in dichloromethane (20 ml) was added
dropwise over 10 min at 5 C. The reaction mixture was allowed
to warm to room temperature and then refluxed for 100 h. The sol-
vent was removed by reduced pressure to leave a fine microcrys-
talline mass which was recrystallised from hot ethanol. The
resulting crystals were isolated by filtration, washed with ethanol
and air-dried. The esters were used as the precursors for the syn-
thesis of the carboxylate ligands. All esters were fully characterised
by 1H, 13C NMR and IR spectroscopies, as well as by elemental anal-
yses, melting point and TLC analysis (given as Supplementary data
in Tables S1–S3).
2.2.2. Synthesis of substituted coumarin acids 2a, 2b and 2d–2i
The coumarin acids 2a, 2b and 2d–2i were synthesised using
the following general procedure. The appropriate ester (1 mmol),
sodium hydroxide solution (2 M, 10 ml) and ethanol (95%, 5 ml)
were heated under reflux for 2 h. After cooling, concentrated
hydrochloric acid (37%) was added drop wise to the solution until
a precipitate formed. The resulting solid was isolated by filtration,
washed with water and dried in a vacuum oven until a constant
mass was obtained.
2.2.3. Synthesis of 8-methoxycoumarin-4-carboxylic acid [8-
OCH3CAH] (2c)
Methyl-8-methoxy-coumarin-4-carboxylate (0.7 g, 3 mmol),
20 ml of hot water and concentrated hydrochloric acid (37%,
2 ml) were added to a round bottom flask. The coumarin did not
dissolve and the resulting suspension was refluxed with stirring
for 11 h. The resulting yellow solid was isolated by filtration,
washed first with water (20 ml) and then with ethanol (20 ml)
and dried in a vacuum oven until a constant mass was obtained.
2.2.4. Synthesis of 6-hydroxycoumarin-4-carboxylic acid [6-OHCAH]
(2j), 7-hydroxycoumarin-4-carboxylic acid [7-OHCAH] (2k) and 8-
hydoxycoumarin-4-carboxylic acid [8-OHCAH] (2l)
6-methoxycoumarin-4-carboxylic acid (2a) (0.44 g, 2 mmol)
and pyridine hydrochloride (3 g, 26 mmol) were irradiated at
200 C for 2 min in a microwave synthesiser. The vessel was cooled
to room temperature and irradiated once more for a further 2 min.
To this, ice-cold water (10 ml) was added, followed by concen-
trated hydrochloric acid (1 M, 10 ml). The reaction mixture was
then extracted with ethyl acetate (40 ml  2) using a separating
funnel. The resulting organic layer was washed with water
(20 ml  2), dried over sodium sulphate and the solvent was re-
moved by reduced pressure. A dark yellow solid (2j) was obtained.
The carboxylate derivatives 7-hydroxycoumarin-4-carboxylic acid
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[7-OHCAH] (2k) and 8-hydoxycoumarin-4-carboxylic acid [8-OH-
CAH] (2l) were synthesised by the same method as that employed
to prepare (2a) except compounds (2b) and (2c), respectively were
used as the starting reagent.
All ligands were fully characterised by 1H, 13C NMR, IR and UV–
Vis spectroscopies, as well as by elemental analyses, melting point
and TLC analysis (Tables 2–5).
2.3. Synthesis of substituted coumarin-4-carboxylatosilver(I)
complexes (3a–3l)
Syntheses of the Ag(I) complexes were conducted in the ab-
sence of light and all complexes were stored in the dark. The
Ag(I) complexes were prepared by the following general method:
coumarin acid (1 mmol) was heated with stirring in a aqueous
solution of sodium hydroxide (0.04 g, 1 mmol in 10 ml of water).
After cooling the resultant suspension to room temperature, sil-
ver(I) nitrate solution (0.170 g, 1 mmol in water (10 ml)) was
added to it, drop wise over 10 min. The suspension was then stir-
red for 1 h and the resulting precipitate was isolated by filtration,
washed with hot ethanol (20 ml) and then with cold water
(20 ml). The solid was then air-dried in the dark. Analytical data
for the Ag(I) complexes is given in Tables 6–9.
2.4. Synthesis of 6-chlorocoumarin-4-carboxylatobis(phenanthro
line)silver(I)3.5H2O (4d), 8-chloro-6-methoxycoumarin-4-carboxy
lato(phenanthroline)silver(I) (4f) and 6-chloro-8-methoxycoumarin-
4-carboxylatebis(phenanthroline)silver(I)3.5H2O (4g)
The Ag(I) phenanthroline adducts (4d, 4f and 4g) were prepared
by the following general method: coumarin acid (0.5 mmol) and
sodium hydroxide solution (0.02 g, 0.5 mmol in water (10 ml))
were stirred for 30 min. A silver nitrate solution (0.085 g, 0.5 mmol
in water (10 ml)) was added drop wise to the coumarin solution,
the resultant yellow suspension was stirred for 1 h. 1,10-Phenan-
throline (0.180 g, 1 mmol) dissolved in ethanol (10 ml) was then
added and the reaction mixture was stirred for a further 2 h. A yel-
low solid was isolated by filtration, washed with water (30 ml),
methanol (20 ml) and allowed to air-dry. Analytical data for the
complexes is given in Tables 6–9.
2.5. Antimicrobial studies
The ligands (2a–l), Ag(I) complexes (3a–l), phenanthroline ad-
ducts (4d, 4f and 4g) and commercially available drugs gentamycin
and vancomycin were screened for their antimicrobial activity.
E. coli (NCIMB 9485), S. aureus (NCIMB 12702) were obtained from
the National Collection of Industrial, Marine and Food. MRSA
(ATCC4300) and P. aeruginosa strains (PA01 and ATCC 27853) were
obtained from the American Type Culture Collection. E. coli and P.
aeruginosa were cultured in Luria Bertani (LB) broth (Sigma) while
S. aureus was cultured in Tryptone Soy Broth (TSB, LabM, UK).
MRSA was cultured in nutrient broth. Bacteria were stored in broth
with 20% glycerol at 80 C, and passaged twice on agar plate (LB
agar, TSA or nutrient agar respectively) before being used in an
experiment. Minimum inhibitory concentrations (MIC) were deter-
mined by broth microdilution. Stock solutions of each compound
to be tested were prepared in DMSO and serially diluted in tripli-
cate using broth (100 ll/well) at a concentration range of 0.195–
200 lM on microtitre plates, after which the final concentration
of DMSO in the cell suspension was not greater than 1%. Overnight
cultures (10 ml) of bacterial strains were inoculated in broth
Table 1
Ligand names, their substituents and positions of R groups for compounds (2a–l).
Ligand name Ligand/molecular formula R groups
R6 R7 R8
6-Methoxycoumarin-4-carboxylic acid 6-OCH3CAH (2a)/C11H8O5 OCH3 H H
7-Methoxycoumarin-4-carboxylic acid 7-OCH3CAH (2b)/C11H8O5 H OCH3 H
8-Methoxycoumarin-4-carboxylic acid 8-OCH3CAH (2c)/C11H8O5 H H OCH3
6-Chlorocoumarin-4-carboxylic acid 6-ClCAH (2d)/C10H5ClO4 Cl H H
6-Bromocoumarin-4-carboxylic acid 6-BrCAH (2e)/C10H5BrO4 Br H H
8-Chloro-6-methoxycoumarin-4-carboxylic acid 8-Cl-6-OCH3CAH (2f)/C11H7ClO5 OCH3 H Cl
6-Chloro-8-methoxycoumarin-4-carboxylic acid 6-Cl-8-OCH3CAH (2g)/C11H7ClO5 Cl H OCH3
7,8-Dichlorocoumarin-4-carboxylic acid 7,8-Cl2CAH (2h)/C10H4Cl2O4 H Cl Cl
8-Flouro-6-bromocoumarin-4-carboxylic acid 8-F-6-BrCAH (2i)/C10H4BrFO4 Br H F
6-Hydroxycoumarin-4-carboxylic acid 6-OHCAH (2j)/C10H6O5 OH H H
7-Hydroxycoumarin-4-carboxylic acid 7-OHCAH (2k)/C10H6O5 H OH H
8-Hydroxycoumarin-4-carboxylic acid 8-OHCAH (2l)/C10H6O5 H H OH
CAH = coumarin-4-carboxylic acid.
Table 2
Analytical data for the coumarin carboxylate ligands (2a–l).
Ligand MW (g/mol) Yield (%) Empirical formula Found (Calc.) (%) M.P (C)a Rfb KM (S cm2 mol1)c
C H
6-OCH3CAH (2a) 220.18 64 C11H8O5 59.94 (60.00) 3.66 (3.66) 246–248 0.66 0.49
7-OCH3CAH (2b) 220.18 84 C11H8O5 59.90 (60.00) 3.55 (3.66) 223–225 0.83 0.48
8-OCH3CAH (2c) 220.18 77 C11H8O5 59.74 (60.00) 3.57 (3.66) 229–232 0.67 0.40
6-ClCAH (2d) 224.60 80 C10H5ClO4 52.98 (53.48) 2.16 (2.24) 230–232 0.75 0.45
6-BrCAH (2e) 269.05 67 C10H5BrO4 44.48 (44.64) 1.84 (1.87) 240–242 0.71 0.45
8-Cl-6-OCH3CAH (2f) 254.62 79 C11H7ClO5 51.70 (51.89) 2.74 (2.77) 282–284 0.73 0.56
6-Cl-8-OCH3CAH (2g) 254.62 94 C11H7ClO5 51.64 (51.89) 3.06 (2.77) 244–246 0.78 0.94
7,8-Cl2CAH (2h) 263.07 97 C10H4Cl2O4 45.62 (46.37) 1.45 (1.56) 249–250 0.75 0.73
8-F-6-BrCAH (2i) 287.04 71 C10H4BrFO4 41.73 (41.84) 1.30 (1.40) 232–233 0.84 1.60
6-OHCAH (2j) 206.15 77 C10H6O5 58.35 (58.26) 3.05 (2.93) 286–288 0.75 0.46
7-OHCAH (2k) 206.15 74 C10H6O5 58.38 (58.26) 3.13 (2.93) 251–253 0.72 0.51
8-OHCAH (2l) 206.15 77 C10H6O5 58.17 (58.26) 3.01 (2.93) 247–249 0.75 0.52
a M.P.s are uncorrected.
b Mobile phase 50:50 ethyl acetate:methanol.
c Recorded in DMSO (4  103 M).
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(100 ml) and incubated at 37 C with agitation, optical density at
600 nm (OD600) was measured and strains were then diluted to
1  106 CFU/ml and seeded at 100 ll/well in microtitre well plates.
Bacteria were also treated with a solvent control (0.5% DMSO) in
control wells. Following 24 h incubation the absorbance was read
in a microtitre plate reader [28].
Each compound was screened at each concentration at least in
triplicate and three independent experiments were carried out.
Table 3
Selected IR and UV–Vis data for the coumarin ligands (2a–l).
Ligand IR (cm1)a UV–Visb
mOH mC@O (lactone) mC@O (acid) kmax (nm) e (M1 cm1)
6-OCH3CAH (2a) 2924 1720 1681 285
354
7457
3000
7-OCH3CAH (2b) 2972 1732 1676 336 11650
8-OCH3CAH (2c) 2948 1737 1677 296 8525
6-ClCAH (2d) 2909 1726 1691 280
327c
8225
4525c
6-BrCAH (2e) 2889 1727 1686 281
328c
7000
3600c
8-Cl-6-OCH3CAH (2f) 2979 1721 1693 288
355
8575
2750
6-Cl-8-OCH3CAH (2g) 2924 1719 1697 295 7175
7,8-Cl2CAH (2h) 2930 1732 1702 294 7575
8-F-6-BrCAH (2i) 3170 1749 1721 285 7950
6-OHCAH (2j) 3079 1736 1681 290
365
8200
3250
7-OHCAH (2k) 3114 – 1697 340 8625
8-OHCAH (2l) 3093 1734 1689 305 9500
a All IR data was recorded as KBr discs.
b All UV–Vis data was recorded in DMSO.
c Shoulder.
Table 4
1H NMR data for coumarin-4-carboxylic acids recorded in d6-DMSO, showing signal in ppm, multiplicity and J values in Hz.
Ligand H4 (vinyl) H5 H6 H7 H8 COOH
6-OCH3CAH (2a) 6.85, s 7.69, d, J = 2.9 3.79, s 7.28, dd, J = 2.9, 9.0 7.41, d, J = 9.0 14.48 (OH)
7-OCH3CAH (2b) 6.66, s 8.09, d, J = 8.9 7.01, dd, J = 2.5, 8.9 3.81, s 7.10, d, J = 2.5
8-OCH3CAH (2c) 6.83, s 7.65, dd, J = 1.8, 7.7 7.29, pt, J = 7.7, 8.2 7.34, dd, J = 1.8, 8.2 3.92, s 14.36 (OH)
6-ClCAH (2d) 6.95, s 8.30, d, J = 2.6 Cl 7.71, dd, J = 2.6, 8.8 7.49, d, J = 8.8
6-BrCAH (2e) 6.99, s 8.45, d, J = 2.4 Br 7.87, dd, J = 2.4, 8.8 7.48, d, J = 8.8
8-Cl-6-OCH3CAH (2f) 6.99, s 7.74, d, J = 2.9 3.86, s 7.56, d, J = 2.9 Cl 14.43 (OH)
6-Cl-8-OCH3CAH (2g) 6.96, s 7.80, d, J = 2.3 Cl 7.45,d, J = 2.3 3.94, s
7,8-Cl2CAH (2h) 6.97, s 8.16, d, J = 8.9 7.66, d
J = 8.9
Cl Cl
8-F-6-BrCAH (2i) 7.07, s 8.28, t, J = 2 Br 8.06, dd, J = 2, 10 F
6-OHCAH (2j) 6.81, s 7.57, d, J = 2.9 9.82 (OH) 7.08, dd, J = 2.9, 8.9 7.31, d, J = 8.9 14.30 (OH)
7-OHCAH (2k) 6.57, s 7.98, d, J = 8.8 6.84, dd, J = 2.4, 8.8 10.73 (OH) 6.77, d, J = 2.4 14.29 (OH)
8-OHCAH (2l) 6.80, s 7.53, dd, J = 2.1, 8.0 7.20, pt, J = 8.0 7.15, dd, J = 2.1, 8.0 10.33 (OH)
Table 5
13C NMR data (ppm) for coumarin-4-carboxylic acids recorded in d6-DMSO.
Ligand C2 (lactone) C3 (vinyl) C4 C5 C6 C7 C8 C9 C10 C11 (carbonyl) OCH3
6-OCH3CAH (2a) 159.8 118.0 143.5 109.5 155.6 119.6 118.6 148.2 116.2 165.4 55.7
7-OCH3CAH (2b) 162.6 114.1 144.1 127.7 112.7 159.9 101.0 155.7 109.1 165.5 56
8-OCH3CAH (2c) 159.3 117.7 144.6 116.3 124.6 114.6 146.8 143.2 117.7 165.5 56.2
6-ClCAH (2d) 159.2 119.8 142.2 126.0 128.5 131.9 118.8 152.4 117.3 164.9 –
6-BrCAH (2e) 159.2 119.9 142.0 129.0 116.4 134.8 119.2 152.9 117.7 165.0 –
8-Cl-6-OCH3CAH (2f) 158.6 119.6 142.9 109.5 155.1 119.0 120.8 143.6 117.6 165.0 56.0
6-Cl-8-OCH3CAH (2g) 158.8 119.8 142.5 116.8 128.5 114.6 147.6 142.3 117.1 163.7 56.7
7,8-Cl2CAH (2h) 158.4 116.2 142.8 126.0 125.5 135.1 119.3 150.4 118.9 164.8 –
8-F-6-BrCAH (2i) 157.9 120.9 141.6a 124.7b 115.2c 121.4d 148.8e 141.5f 119.2g 164.6 –
6-OHCAH (2j) 159.7 117.6 143.7 110.9 153.8 120.3 117.8 147.0 116.1 165.4 –
7-OHCAH (2k) 160.1 112.9 144.4 128.1 113.4 161.5 102.6 155.8 107.9 165.4 –
8-OHCAH (2l) 159.4 117.2 144.9 116.5 124.5 118.6 144.9 142.5 116.5 165.5 –
a d, JC–F = 2.4.
b d, JC–F = 3.6.
c d, JC–F = 8.5.
d d, JC–F = 20.4.
e d, JC–F = 251.
f d, JC–F = 11.5.
g d, JC–F = 1.8.
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The MIC90 values were determined as the concentration of test
compound which inhibited 90% visible growth in 24 h.
2.5.1. Biofilm assay
Strains were cultured in Cation adjusted Mueller Hinton broth
(CAMHB) overnight and inoculated in fresh CAMHB to reach an
OD600 of 0.6. Bacterial biofilms were formed on pegs of a modified
polystyrene lid by inoculating 100 ll of bacterial suspension
(106 CFU/ml) to each well of a polystyrene plate and incubated
for 20 h [29]. Peg lids were rinsed three times in sterile water
and placed into 96 well plates containing a range of test dilutions
in 100 ll CAMHB and incubated for 18 h. The peg lids were placed
0.5% crystal violet solution for 15 min, rinsed and dried for several
hours. The pegs were then incubated in 95% ethanol with 0.05%
Triton X 100 for 15 min and absorbance measured at 590 nm.
The BIC90 values, biofilm inhibitory concentration, were deter-
mined as the minimal concentration of compound needed to re-
duce biofilm formation by 90% after 18 h treatment.
3. Results and discussion
3.1. Synthesis and characterisation of the ligands
The carboxylate ligands were synthesised by first preparing
their corresponding esters (1a–i) via an aromatic electrophilic sub-
stitution reaction between the conjugated base of substituted phe-
nols and a vinyl triphenylphosphonium salt [30]. This reaction
which involved refluxing the appropriate phenol with triphenyl-
phosphine and dimethylacetylene dicarboxylate in dichlorometh-
ane for 100 h yielded the starting esters. The products were
isolated by recrystallisation from ethanol and characterised by
standard techniques. The acid derivatives were then synthesised
by either acid or base hydrolysis of the corresponding ester or a
demethylation reaction (Scheme 1). The acid derivative [8-OCH3-
CAH] (2c) was synthesised by refluxing the ester in water and
10% hydrochloric acid solution with an average reaction time of
11 h. Ester 1c was not soluble in the acid/water mixture and re-
mained as a suspension; the suspended product was then isolated
by filtration. The acid derivatives 2a, 2b and 2d–i could also be syn-
thesised by this method however better yields were obtained by
base hydrolysis. The acid 2c could also be synthesised by base
hydrolysis but gave a higher yield when made using acid hydroly-
sis. Synthesis of the hydroxy substituted acid derivatives 2j–l was
carried out by demethylation reaction of the corresponding meth-
oxy substituted acids Scheme 2. Demethylation was achieved by a
microwave-assisted reaction using pyridine hydrochloride fol-
lowed by quenching with HCl and ice water; products were ex-
tracted using ethyl acetate [31]. Physical data and empirical
formulae are presented in Table 2. All of the ligands had good sol-
ubility in a range of organic solvents.
IR spectral data for the ligands is given in Table 3. The formation
of the coumarin acid derivatives was confirmed by the appearance
of the characteristic acid bands, mC@O and mOH. There were two mC@O
bands corresponding to the mC@O (acid) and the mC@O (lactone) and
these were observed at between 1721–1677 and 1720–1737 cm1
respectively. In a previous study on coumarin-3-carboxylate the
lower frequency band was assigned to the lactone carbonyl though
in this molecule intramolecular hydrogen bonding between the
lactone carbonyl and hydrogen of the acid was thought to lower
the frequency of the lactone carbonyl [32]. In the coumarin-4-car-
boxylate ligands the assignment of the two mC@O bands was based
on consideration of the lactone as a cyclic ester in which the
carbonyl group of a,b-unsaturated esters occurs at about 1730–
1715 cm1 and the carbonyl of a d-lactone (six-membered ring) oc-
curs in the same region as unconjugated esters (1750–1735 cm1)
Table 6
Analytical data for the Ag(I) complexes 3a–l and 4d, 4f and 4g.
Complex MW (g/
mol)
Yield
(%)
Empirical
formula
Found (Calc.) (%) M.P
(C)
KM
(S cm2 mol1)
C H N Ag
[Ag(6-OCH3CA)] (3a) 327.04 68 C11H7AgO5 39.41
(40.40)
2.03
(2.16)
– 33.01
(32.98)
>300 10.85
[Ag(7-OCH3CA)] (3b) 327.04 68 C11H7AgO5 39.67
(40.40)
2.13
(2.16)
– 33.03
(32.98)
>300 10.23
[Ag(8-OCH3CA)] (3c) 327.04 57 C11H7AgO5 40.22
(40.40)
2.27
(2.16)
– 32.60
(32.98)
243–
246
10.10
[Ag(6-ClCA)] (3d) 331.46 63 C10H4ClAgO4 36.05
(36.24)
1.19
(1.22)
– 31.92
(32.54)
>300 12.55
[Ag(6-BrCA)] (3e) 375.91 76 C10H4AgBrO4 31.73
(31.95)
1.15
(1.07)
– 28.13
(28.70)
>300 15.71
[Ag(8-Cl-6-OCH3CA)] (3f) 361.48 93 C11H6AgClO5 36.55
(36.55)
1.67
(1.67)
– 29.51
(29.84)
>300 11.42
[Ag(6-Cl-8-OCH3CA)] (3g) 361.48 66 C11H6AgClO5 37.40
(36.55)
1.80
(1.67)
– 29.76
(29.84)
>300 11.13
[Ag(7,8-Cl2CA)] (3h) 365.90 77 C10H3AgCl2O4 32.14
(32.82)
0.67
(0.83)
– 28.90
(29.48)
>300 10.87
[Ag(8-F-6-BrCA)] (3i) 393.90 87 C10H3AgBrFO4 30.39
(30.49)
0.60
(0.77)
– 26.91
(27.38)
>300 13.73
[Ag(6-OHCA)] (3j) 313.01 64 C10H5AgO5 37.95
(38.37)
1.93
(1.61)
– 34.39
(34.46)
>300 8.88
[Ag(7-OHCA)] (3k) 313.01 64 C10H5AgO5 38.10
(38.37)
1.59
(1.61)
– 33.90
(34.46)
>300 8.78
[Ag(8-OHCA)] (3l) 313.01 32 C10H5AgO5 38.03
(38.37)
2.01
(1.61)
– 33.94
(34.46)
>300 8.81
[Ag(phen)2(6-ClCA)]3.5H2O (4d) 754.92 33 C34H27AgClN4O7.5 53.65
(54.09)
2.80
(3.60)
7.99
(7.42)
13.54
(14.29)
227–
229
–
[Ag(phen)(8-Cl-6-OCH3CA)] (4f) 541.69 63 C23H14AgClN2O5 50.77
(51.00)
2.38
(2.61)
5.22
(5.17)
18.93
(19.19)
227–
230
–
[Ag(phen)2(6-Cl-8-OCH3CA)]3.5H2O
(4g)
784.95 34 C35H29AgClN4O8.5 53.42
(53.55)
3.47
(3.72)
6.97
(7.14)
14.15
(13.74)
226–
227
–
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Table 7
Selected IR and UV–Vis data for the Ag(I) complexes 3a–l and 4d, 4f and 4g.
IR (cm1)a UV–Visb
Complex mC@O masym(OCO) msym(OCO) Dm(OCO) kmax (nm) e (M1 cm1)
[Ag(6-OCH3CA)] (3a) 1694 1625 1402 223 278
340
10200
4925
[Ag(7-OCH3CA)] (3b) 1698 1618 1399 219 322 13350
[Ag(8-OCH3CA)] (3c) 1703 1606 1395 211 289 14025
[Ag(6-ClCA)] (3d) 1704 1604 1390 214 274
320
11650
7425
[Ag(6-BrCA)] (3e) 1716 1615 1411 204 274
321
10300
6175
[Ag(8-Cl-6-OCH3CA)] (3f) 1702 1626 1395 231 280
337
11200
4525
[Ag(6-Cl-8-OCH3CA)] (3g) 1713/1682 1617 1385 232 285 13400
[Ag(7,8-Cl2CA)] (3h) 1717/1693 1619 1389 230 283 11025
[Ag(8-F-6-BrCA)] (3i) 1693 1609 1398 211 275
320c
9550
3700
[Ag(6-OHCA)] (3j) 1713 1623 1416 207 280
345
10775
4800
[Ag(7-OHCA)] (3k) 1706 1621 1384 237 325 15225
[Ag(8-OHCA)] (3l) 1685 1595 1384 211 295 29825
[Ag(phen)2(6-ClCA)]3.5H2O (4d) 1727 1620 1372 248 270
328c
52550
6275
[Ag(phen)(8-Cl-6-OCH3CA)] (4f) 1726 1617 1380 237 270
342c
43025
5525
[Ag(phen)2(6-Cl-8-OCH3CA)]3.5H2O (4g) 1715 1630 1385 245 270 48500
a All IR data was recorded as KBr discs.
b All UV–Vis data was recorded in DMSO.
c Shoulder.
Table 8
1H NMR data for Ag(I) complexes 3a–l and 4d, 4f and 4g, showing signal in ppm, multiplicity and J values in Hz recorded in d6-DMSO.
Compound C–Hvinyl H5 H6 H7 H8
[Ag(6-OCH3CA)] (3a) 6.37, s 7.71, d, J = 3.1 3.77, s 7.19, dd, J = 3.1, 9.0 7.30, d, J = 9.0
[Ag(7-OCH3CA)] (3b) 6.18, s 8.04, d, J = 8.8 6.94, dd, J = 2.5, 8.8 3.86, s 6.98, d, J = 2.5
[Ag(8-OCH3CA)] (3c) 6.35, s 7.61, dd J = 2.4, 7.0 7.22, pt, J = 7.0, 8.2 7.26, dd, J = 2.4, 8.2 3.89, s
[Ag(6-ClCA)] (3d) 6.52, s 8.33, d,J = 2.6 Cl 7.67, dd, J = 2.5, 8.8 7.44, d, J = 8.8
[Ag(6-BrCA)] (3e) 6.53, s 8.45, d,J = 2.5 Br 7.76, dd, J = 2.4, 8.8 7.38, d, J = 8.8
[Ag(8-Cl-6-OCH3CA)] (3f) 6.43, s 7.73, d, J = 2.9 3.86, s 7.42, d, J = 2.9 Cl
[Ag(6-Cl-8-OCH3CA)] (3g) 6.49, s 7.80, d, J = 2.3 Cl 7.36, d, J = 2.3 3.93, s
[Ag(7,8-Cl2CA)] (3h) 6.52, s 8.20, d, J = 8.7 7.62, d, J = 8.7 Cl Cl
[Ag(8-F-6-BrCA)] (3i) 6.59, s 8.31, s, Br 7.91, dd, J = 2, 10.0 F
[Ag(6-OHCA)] (3j) 6.33, s 7.52, d, J = 2.9 9.76 (OH) 7.01, dd, J = 2.9, 8.9 7.31, d, J = 8.9
[Ag(7-OHCA)] (3k) 6.12, s 7.93, d, J = 8.8 6.77, dd, J = 2.4, 8.8 10.60 (OH) 6.70, d, J = 2.4
[Ag(8-OHCA)] (3l) 6.26, s 7.46, dd, J = 1.7, 8.0 7.11, pt, J = 8.0 7.07, dd, J = 1.7, 8.0 10.11 (OH)
[Ag(phen)2(6-ClCA)]3.5H2O (4d) 6.62, s 8.29, d, J = 2.6 Cl 7.63, dd, J = 2.6, 8.9 7.42, d, J = 8.8
[Ag(phen)(8-Cl-6-OCH3CA)] (4f) 6.46, s 7.71, d, J = 2.9 3.80, s 7.39, d, J = 2.9 Cl
[Ag(phen)2(6-Cl-8-OCH3CA)]3.5H2O (4g) 6.35, s 7.81, d, J = 2.4 Cl 7.23, d, J = 2.4 3.90, s
Table 9
13C NMR data (ppm) for the Ag(I) complexes, 3a–l and 4d, 4f and 4g recorded in d6-DMSO.
Compound C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 OCH3
[Ag(6-OCH3CA)] (3a) 160.9 112.4 153.6 110.9 155.6 118.9 117.2 148.3 118.1 166.9 55.7
[Ag(7-OCH3CA)] (3b) 162.1 112.1 153.2 128.9 110.6 161.0 100.6 155.6 109.0 167.4 55.8
[Ag(8-OCH3CA)] (3c) 160.5 111.5 153.6 118.9 123.8 113.8 146.6 143.2 117.7 167.0 56
[Ag(6-ClCA)] (3d) 160.3 114.1 151.6 127.2 128.0 131.3 118.5 152.4 118.8 166.7 –
[Ag(6-BrCA)] (3e) 160.3 113.6 151.8 130.1 115.8 134.0 118.7 152.8 119.3 166.4 –
[Ag(8-Cl-6-OCH3CA)] (3f) 159.9 113.2 153.5 110.5 154.8 118.5 120.2 143.6 119.2 166.5 55.9
[Ag(6-Cl-8-OCH3CA)] (3g) 159.9 114.3 152 117.9 127.8 113.9 147.5 142.2 118.5 166.5 56.5
[Ag(7,8-Cl2CA)] (3h) 159.5 112.5 153.1 127.2 124.9 134.3 118.9 150.4 117.9 166 –
[Ag(8-F-6-BrCA)] (3i) 159.0 114.6 151.5 124.7 d,
JC–F = 3.5
114.5 d,
JC–F = 8.8
120.3 d,
JC–F = 20.5
148.7 d,
JC–F = 251
141.4 d,
JC–F = 11.2
120.9 165.8 –
[Ag(6-OHCA)] (3j) 161.0 111.8 153.7 112.3 153.4 119.7 117.1 147.1 117.8 167.4 –
[Ag(7-OHCA)] (3k) 160.8 107.4 154.2 129.1 112.7 161.2 101.9 155.6 109.5 167.5 –
[Ag(8-OHCA)] (3l) 160.8 110.6 155.2 117.7 123.7 117.9 142.6 144.6 118.3 167.2 –
[Ag(phen)2(6-ClCA)]3.5H2O (4d) 160.0 115.6 149.0 126.9 128.0 131 118.3 152.4 118.4 165.0 –
[Ag(phen)(8-Cl-6-OCH3CA)] (4f) 159.8 114.2 151.6 110.6 154.9 118.5 120.2 143.7 119.1 165.1 56.0
[Ag(phen)2(6-Cl-8-OCH3CA)]3.5H2O (4g) 160.3 112.2 154.3 119.3 127.5 113.6 142.3 147.4 118.8 166.3 56.5
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depending on the position of unsaturation. Also important to note
is that a,b-unsaturated and aryl conjugated acids show absorption
for the carbonyl of the dimer at 1710–1680 cm1 [33]. Therefore
the mC@O band appearing at lower wavenumber in the IR spectra
of the coumarin ligands may be assigned to mC@O (acid). Compari-
son of the spectra of the acids with those of the esters show that
there is a new carbonyl band in the spectra of the acids which
can be attributed to mC@O (acid).
The 1H and 13C NMR spectra of the ligands were recorded in d6-
DMSO and the data are reported in Tables 4 and 5 respectively. The
most characteristic signal in the 1H NMR spectra of carboxylic acids
is that of the OH group though not surprisingly in d6-DMSO it was
not always observed (dOH varied from 14–9.82 ppm). A comparison
of the 1H NMR spectra of the acids with those of the corresponding
esters shows the loss of the –CH3 of the methyl signal at approxi-
mately 3.9 ppm confirming hydrolysis of the ester. The 13C NMR
signals of the coumarin acid ligands were assigned with the help
of DEPT, HSQC and HMBC 2D experiments. The loss of the signal
for the methyl ester carbon was observed in all of the spectra of
the acids indicating that hydrolysis was complete.
3.2. Synthesis and characterisation of the complexes
The silver(I) complexes of the coumarin acids were formed by
reaction with silver nitrate in aqueous solution in a 1:1 M ratio
(Scheme 3). The acids were first deprotonated using NaOH prior
to addition of silver nitrate. All Ag(I) complexes were isolated as
insoluble precipitates from the reaction media and when dried
and stored in the dark they appeared to be air and moisture stable.
The complexes were soluble in DMSO only. Elemental analyses of
the complexes 3a–l, were in agreement with the proposed 1:1
ligand:silver ratio (Table 6). Only the phen-containing complexes
of ligands 2d, 2f and 2gwere synthesised in acceptable purity. Pre-
vious studies have shown that inclusion of phen ligands in the
coordination sphere of the cation not only improves solubility
but has significantly improved bioactivity towards a number of
clinically relevant species [34]. 4d, 4f and 4g were synthesised
by firstly preparing the corresponding Ag(I) complex (3d, 3f and
3g) and leaving the product in the reaction solution. A solution
of 1,10-phen in ethanol was then added to this solution in a molar
ratio of 1:1:2 ligand:metal:phen. The phen complexes were soluble
in DMSO (hot) only. Elemental analyses indicated a metal to ligand
ratio of 1:1:2 for 4d and 4g with 3.5 water molecules in the
formulation. A ratio of 1:1:1 ligand:metal:phen was observed for
4f (Table 6). All attempts at recrystallisation of the complexes iso-
lated failed. Complex stability in DMSO solution was confirmed via
measurement of 1H NMR spectra of d6-DMSO samples of com-
plexes stored over a period of months in the dark. No appreciable
differences in the spectra were noted in this time.
3.2.1. IR spectra
The previously prepared complexes of coumarin-3-carboxylates
allowed the identification of complexes, which whilst showing
good antimicrobial activity, were polymeric in nature and had poor
solubility in common organic solvents. We thought that might be
related to the proximity of the carboxylate and lactone carbonyls
which allowed for the formation of chelate complexes. Shifts of be-
tween 10 and 40 cm1 in the lactone carbonyl seemed to confirm
this coordination. Use of the 4-positon on the lactone ring for the
carboxylate groups does not allow for the same type of coordina-
tion here and it was thought coordination to the carboxylate group
alone would be favoured over bonding at the lactone carbonyl.
On examination of the IR spectra of the complexes, in compar-
ison to those of the ligands, the most significant observation was
the disappearance of the acid carbonyl band and the appearance
of the asymmetric (masym (OCO)) and symmetric (msym (OCO))
stretching frequencies. The masym (OCO) and msym (OCO) stretching
frequencies and the Dm (OCO) values for the Ag(I) complexes are
given in Table 7. The complexes (3a–l) had Dm (OCO) values
>200 cm1 indicating unidentate carboxylate coordination to the
Ag(I) centre [35] and are consistent with those previously reported
for Ag(I) complexes of coumarin-3-carboxylates [36]. Interestingly,
the mC@O (lactone) stretching vibration was shifted in all of the
complexes by 11–56 cm1 relative to the free ligand, upon forma-
tion of the Ag(I) complexes as was observed in the coumarin-3-car-
boxylates. Several reports have attributed such a shift to the
participation of the coumarin lactone carbonyl in complexation
to the metal ion [37–39] but it has also been reported for other
coumarin derivatives where the lactone was not involved in com-
plexation [40,41]. In the latter instance the shift may be attributed
to an increase in polarity of the lactone ring which can occur upon
metal complexation. The insolubility of the complexes along with
the IR data would suggest that they exist in the solid state as poly-
meric structures with extensive hydrogen bonding common to car-
boxylate structures as well as possible bonding of Ag(I) to both the
deprotonated carboxylate oxygen and lactone carbonyl oxygen of
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Scheme 1. General reaction scheme for the synthesis of the coumarin esters (1a–i) and the acids (2a–i).
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neighbouring ligands. Changes observed in the weak absorption
bands at 400–600 cm1 in the spectra of the complexes were as-
signed to the M–O stretching vibrations [42,43].
The IR spectra of the phen-containing complexes 4d, 4f and 4g
were similar to each other and showed new absorption bands char-
acteristic of chelating phenanthroline [44], these occurring at ca.
1510, 841 and 726 cm1 (Table 7). The Dm (OCO) values of the
phen-complexes were also found to be >200 cm1 indicating uni-
dentate coordination of the coumarin carboxylate group to the
Ag(I) ion in all cases. The presence of water molecules was con-
firmed by the broad band observed at 3400 cm1 in each of the
spectra. The changes observed in the weak absorption bands at
400–600 cm1 in the IR spectra of the complexes is attributed to
the M–O and M–N stretching frequencies.
3.2.2. NMR spectra
Peak assignments (see Fig. 1 for atom numbering) for the 1H and
13C NMR spectra of all the Ag(I) complexes in d6-DMSO solution are
given in Tables 8 and 9. In general, small shifts were observed for
the aromatic protons upon complex formation but the greatest
complexation induced shift (CIS) was observed for the vinyl proton
H3 due to its proximity to the carboxylate group and this was
shifted upfield by 0.45–0.56 ppm. The 13C NMR spectra of the com-
plexes revealed that the signals for the aromatic carbons (C5–C8)
experienced a number of small shifts and the signal for the lactone
carbonyl (C2) was mainly unaffected by complexation. The most
significant shifts were observed for the carbons closest to the site
of complexation, C3, C4 and C11. The signal for C4 experienced
the greatest shift and was shifted downfield by 9.1–10.5 ppm.
The carboxylate carbon, C11 was also shifted slightly downfield
by 1–4 ppm and the vinyl carbon, C3 was found to be shifted
slightly more upfield by 2–6.6 ppm in the spectra of the Ag(I) com-
plexes. Similar patterns were also reported for the spectra of the
Ag(I) complexes of the coumarin-3-carboxylates [35].
From the NMR data of the complexes it is likely that binding of
the coumarin ligands to Ag(I) in solution phase is through uniden-
tate coordination of the carboxylate group. Comparison of the 13C
NMR spectra of the free ligands and their Ag(I) complexes (Tables
5 and 9) identified that the carbons of the carboxylate (C11) and
lactone (C2) functionalities are only slightly deshielded upon com-
plexation. This was also observed for the Ag(I) complexes of the
coumarin-3-carboxylates and it was reported that the noted small
shifts may be as a result of hydrogen-bonding present in the free
ligands in DMSO solution.
The 1H NMR spectra of the phenanthroline-containing com-
plexes 4d, 4f and 4g has four additional signals at ca. 9.17, 8.77,
8.21, 8.01 ppm corresponding to the protons of the phenanthroline
ligands. The integrals confirm that the 2:1 phen:coumarin ratio for
complexes 4d and 4g and the 1:1 phen:coumarin ratio for 4f. On
comparison with the spectra of the free phenanthroline ligand,
small downfield shifts for the three of protons were observed in
the spectra of all the complexes, similar to those noted for the
mixed ligand Ag(I) complex of 4-hydroxy-3-nitro-2H-chromen-2-
one [25]. There are six signals observed in the 13C NMR spectra
of the complexes representing the non-equivalent carbons of the
phenanthroline ligands all of which displayed relatively small CIS.
3.2.3. Molar conductivity
The molar conductivities of the Ag(I) complexes, 3a–l (Table 6)
were determined from conductance measurements obtained in
DMSO solvent at 4.0  l03 M concentrations. The values were in
the range of 8.87–15.71 S cm2 mol1 and were similar to those re-
ported for other coumarin complexes recorded in DMSO and would
suggest their non-electrolytic character [45]. The molar conductiv-
ity of the mixed ligand complexes 4d, 4f and 4g was not recorded
due to the poor solubility of the complexes in DMSO solvent.
3.3. Antimicrobial activity of coumarin ligands and their Ag(I)
complexes
The Ag(I) complexes (3a–l, 4d, 4f, 4g), the free ligands and the
metal salt AgNO3 were screened for their activity against two Gram
negative bacteria E. coli (NCIMB9485) and P. aeruginosa (ATCC
27853) and two strains of the Gram positive bacteria S. aureus, a
methicillin sensitive strain, NCIMB12702 and a methicillin-resis-
tant strain, ATCC4300 (MRSA). Commercial drugs vancomycin
and gentamycin were also tested for their activities against rele-
vant microbial strains. The antimicrobial activity of the compounds
given in Table 10 and are expressed as MIC90 values (minimum
concentration required to inhibit 90% of visible cell growth in
24 h). Although a number of coumarin-derived compounds have
previously shown antimicrobial activity [45], none of the synthes-
ised metal-free coumarin ligands or phenanthroline showed any
inhibition of growth at the maximum concentrations tested.
The Ag(I) complexes showed some antibacterial activity partic-
ularly against E. coli and P. aeruginosa. The activity of the com-
plexes 3a–f, 3i–l tested against E. coli were slightly less than that
of silver nitrate (MIC90 = 36.1 lM) and generally all were greater
in activity than gentamycin (60.3 lM). The type of substituent
present on the benzene ring did not seem to influence their activity
significantly against E. coli however the activity of the complexes
(3a–h) tested against the P. aeruginosa ATCC 27853 did vary
depending on the type of substituent present on the benzene ring.
Complexes with a methoxy substituent only (3a–c) had similar
activity and were comparable to that of AgNO3 (92.8 lM). The
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complexes with halogen substituents (3d–h) were observed to
have greater activity. Compounds with electron-withdrawing sub-
stituents such as halogens can have increased lipophilicity and
hence an improved cell permeability of microorganisms. An in-
crease in liposolubility is an important factor for antimicrobial
activity and several groups have reported that the influence of a
halogen substituent in a compound can affect its activity by steric
or electronic effects [46–48]. The dichloro substituted complex
[Ag(7,8-Cl2CA)] (3h) showed activity (MIC90 = 90 lM) similar to
the methoxy substituted complexes. The decrease in activity is
likely as a result of its poor solubility and indeed meant that the
complex had to be tested as a suspension.
Six of the complexes (3a–f) were also tested against P. aerugin-
osa (PA01) either in planktonic form or as a biofilm (MIC90 values
given in Table 11). Overall the activity of the substituted com-
plexes against the planktonic strain was comparable to that found
against P. aeruginosa ATCC 27853. The sensitivity of different
strains of the same organism to a single antibiotic can depend upon
the morphological and physiological characteristics of the strains
[49] but there was no significant variation noted here.
The activity of silver and its complexes, including silver sulfadi-
azine, against P. aeruginosa biofilms has been studied previously by
Bjarnsholt et al. and they found that the bactericidal concentration
of silver needed to eliminate the bacterial biofilm was between 10
and 100 times greater than that used to eliminate planktonic bac-
teria [50]. Complexes 3a–f and AgNO3 were found to be more ac-
tive against the biofilm form of PA01 than the planktonic form
and all BIC values were comparable. The complexes were approx-
imately 4–6 times more potent against the biofilm than the plank-
tonic form. This is clinically important as bacteria living in a
biofilm can be up to 1000 times more resistant to antimicrobial
agents than planktonic bacteria [51]. The antibacterial mechanism
of silver ions has been well studied and it is possible that in these
studies the silver complexes act by disrupting the signal processes
associated with biofilm formation as the mechanisms involved in
biofilm resistance to antimicrobials may differ from those respon-
sible for antimicrobial resistance in planktonic bacteria. Biofilm
resistance is multifactorial and includes a diffusion barrier, seques-
tration of antibiotics within the glucan polymers, slower growth,
reduced oxygen concentrations at the base of the biofilm [52,53].
As such only a combination of different mechanisms could account
for the levels of resistance seen in biofilm communities [54]. The
fact that silver is said to have broad-spectrum activity in which it
attacks multiple sites of microorganisms may be a factor in the
enhanced activity shown by the silver complexes against P. aeru-
ginosa biofilm.
The phenanthroline containing complexes, 4d, 4f and 4g and
free phenanthroline were tested for their activity against MRSA
(ATCC4300) and P. aeruginosa (ATCC 27853). Surprisingly their sol-
ubility in the solvent was poor and as such they were tested as sus-
pensions. Metal-free phenanthroline has previously been reported
to have significant activity against a number of microbes [55] how-
ever it was found to be inactive against the microbes used in this
study (MIC90 > 100 lM). There is often variation in sensitivity of
different strains of the same species to antimicrobial agents. Intro-
duction of phenanthroline as a second ligand to the Ag(I) com-
plexes improved the activity of 4d and 4g against P. aeruginosa
only. The increase in activity would suggest a synergistic effect of
both ligands and the silver ion. The MIC90 values for the com-
pounds against MRSA were all greater than 100 lM and so the
introduction of phenanthroline did not increase the activity of
the compounds against these microbes.
The activity of the complexes may be due to a synergistic effect
of both ligand and metal ion or it may be as a result of the Ag(I) ion
only. Silver has the ability to bind to the metal binding sites in pro-
teins (sulfhydryl groups) thereby inactivating enzymes and block-
ing the respiratory chain of microorganisms [56]. The antimicrobial
activity of several Ag(I) complexes of oxygen donor ligands is inde-
pendent of whether the ligand itself possesses antimicrobial activ-
ity and results from the weaker bonding property of the Ag–O bond
Table 10
Antimicrobial Activity of Compounds (MIC90).
Compound S. aureus NCIMB12702 MRSA E. coli NCIMB9485 P. aeruginosa ATCC27853
[Ag(6-OCH3CA)] (3a) 123.1 >100 75.3 94.9
[Ag(7-OCH3CA)] (3b) 174.7 >100 46.6 94.0
[Ag(8-OCH3CA)] (3c) 188.0 >100 47.3 94.2
[Ag(6-ClCA)] (3d) 181.2 >100 46.7 63.5
[Ag(6-BrCA)] (3e) 102.6 >100 47.1 75.3
[Ag(8-Cl-6-OCH3CA)] (3f) 97.6 >100 47.1 67.2
[Ag(6-Cl-8-OCH3CA)] (3g) – >100 – 52.8
[Ag(7,8-Cl2CA)] (3h) – >100 – 90.5
[Ag(8-F-6-BrCA)] (3i) 139.5 >200 46.9 –
[Ag(6-OHCA)] (3j) 111.4 >200 47.3 –
[Ag(7-OHCA)] (3k) 108.2 >200 46.9 –
[Ag(8-OHCA)] (3l) 99.4 >200 47.7 –
[Ag(phen)2(6ClCA)]3.5H2O (4d) – >100 – 55.7
[Ag(phen)(8-Cl-6-OCH3CA)] (4f) – >100 – 71.4
[Ag(phen)2(6-Cl-8-OCH3CA)]3.5H2O (4g) – >100 – 48.5
AgNO3 152. >100 36.1 92.8
Ligands (2a–l) >200 >200 >200 >100
Phenanthroline >100 >100
Gentamycin 33.5 60.3
Vancomycin 3.0 >10
Amphothericin B – –
Table 11
Antimicrobial activity of selected Ag(I) complexes (3a–f) against Pseudomonas
aeruginosa (PA01) expressed as MIC90 and BIC90.
Compound Pseudomonas aeruginosa (PA01)
MIC90 (lM) BIC90 (lM)
Ligands (2a–f) >200 >200
[Ag(6-OCH3CA)] (3a) 95.8 (±0.4) 25.0 (±1.3)
[Ag(7-OCH3CA)] (3b) 96.6 (±1.4) 18.3 (±3.6)
[Ag(8-OCH3CA)] (3c) 93.2 (±0.4) 19.6 (±3.8)
[Ag(6-ClCA)] (3d) 91.7 (±1.0) 16.9 (±2.4)
[Ag(6-BrCA)] (3e) 154.2 (±30.2) 21.2(±0.5)
[Ag(8-Cl-6-OCH3CA)] (3f) 95.6 (±1.0) 15.2 (±3.2)
AgNO3 95.2 (±0.9) 18.1 (±3.7)
MIC90 values (minimum concentration required to inhibit 90% of visible cell growth
in 24 h).
BIC90 values (biofilm inhibitory concentration, defined as the minimal concentra-
tion of compound to reduce biofilm formation by 90% after 18 h treatment.).
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and the ease of ligand replacement of the Ag(I) complexes with
biological ligands such as those with O, N or S donor atoms. The li-
gands are likely acting as carriers for the Ag(I) ion and the magni-
tude of the antimicrobial properties of the complexes is related to
the ease with which they participate in ligand exchange reactions
[57].
The complexation of the coumarin-4-carboxylates to Ag(I) re-
sulted in enhanced antibacterial activity particularly towards
E. coli and P. aeruginosa. Gram negative bacteria are generally less
sensitive to biocides than Gram positive bacteria because of their
outer membrane or envelope. The outer cell layer of Gram negative
bacteria consists of an outer membrane, a thin layer of peptidogly-
can and a periplasmic space and an inner membrane [58]. One of
the effects of the outer envelope is to form an impermeable barrier
that protects the microorganism from toxic molecules such as bio-
cides and antibiotics. It allows the slow penetration of hydrophobic
molecules and this decrease in penetration is responsible for the
resistance of Gram negative bacteria to certain antibiotics. Several
biocides can destabilise and disorganise the outer membrane thus
gaining entry to the bacterial cell. Antibiotic passage may also oc-
cur by passive or facilitated diffusion through water-filled chan-
nels. The uptake and penetration process of the biocide will be
influenced by interactions with all structures it encounters. There-
fore the penetration of a biocide or antibiotic may often be deter-
mined by its physical properties rather than its specific structure.
An optimal hydrophilic–lipophilic balance will enable the best
penetration across the outer membrane and a complex mix of por-
tioning and passive diffusion processes is thus likely to determine
the progress of a biocide across the Gram-negative outer envelope
[59]. It is therefore likely that the coordination of Ag(I) to the cou-
marin-4-carboxylate ligands results in a biocide with suitable
physical properties which are capable of penetration of the outer
membrane. The process in which it gains access is likely to be
through an optimal hydrophilic–lipophilic balance. The increased
activity of those complexes which had a halogen substituent also
demonstrates the importance of lipophilicity for the activity of
the complexes.
4. Conclusion
A number of novel Ag(I) coumarin–carboxylate complexes have
exhibited moderate antimicrobial activity towards E. coli and P.
aeruginosa. Some of the complexes showed greater activity against
E. coli than gentamycin and were comparable in activity or greater
than AgNO3 against P. aeruginosa grown planktonically or as a bio-
film. Six of the complexes (3a–f) were approximately 4–6 times
more potent against the biofilm compared to planktonic bacteria
and introduction of phenanthroline as a second ligand to the
Ag(I) complexes improved the activity of 4d and 4g against a strain
of P. aeruginosa only. The poor solubility of the complexes would
likely limit their use as potential oral drugs but they could be used
in a number of therapeutic applications including coatings, medical
devices, catheters, wound dressings, sutures etc. We have previ-
ously shown the potential of Ag(I) coumarin carboxylates for use
as effective biocides in hygienic thin film coatings and the novel
Ag(I) complexes in this study can now be investigated for use as
additives for hygienic coatings.
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